TNFRSF1A polymorphisms rs1800693 and rs4l49584 in patients with multiple sclerosis

Neurology

Volumn 80, Issue 22, 2013, Pages 2010-2016

  Comabella, Manuel ^a   Caminero, Ana B ^a   Malhotra, Sunny ^a   Agulló, Luis ^a   Fernández, Oscar ^b   Reverter, Ferran ^c   Vandenbroeck, Koen ^d,e   Rodríguez Antiguedad, Alfredo ^f   Matesanz, Fuencisla ^g   Izquierdo, Guillermo ^h   Urcelay, Elena ⁱ   López Larios, Arturo ⁱ   Sánchez, Alex ^j   Otero, Susana ^a   Tintoré, Mar ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e BASQUE FOUNDATION FOR SCIENCE   (Spain)

^f HOSPITAL DE BASURTO   (Spain)

^g INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HUVH   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CELL SURFACE; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FLOW CYTOMETRY; FLU LIKE SYNDROME; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER 1A GENE;

ADULT; AGE FACTORS; AGE OF ONSET; ALLELES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUTATION; POLYMORPHISM, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEVERITY OF ILLNESS INDEX;

EID: 84879482978     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318294b2d6     Document Type: Article

References (17)

1. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009;4:776-782.
2. International Multiple Sclerosis Genetics Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-219.
3. Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012;488:508-511.
4. Dode C, Andre M, Bienvenu T, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002;46:2181-2188.
5. Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 2002;81:349-368.
6. Aksentijevich I, Galon J, Soares M, et al. The tumornecrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001;69:301-314.
7. Kumpfel T, Hoffmann LA, Rübsamen H, et al. Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. Arthritis Rheum 2007;56:2774-2783.
8. Kumpfel T, Hoffmann LA, Pellkofer H, et al. Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases. Neurology 2008;71:1812-1820.
9. Swaminathan B, Matesanz F, Cavanillas ML, et al. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain. J Neuroimmunol 2010;223:100-103.
10. International Multiple Sclerosis Genetics Consortium. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study. PLoS One 2011;6:e18813.
11. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-1151.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 2001;25:402-408.
13. Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol 2011;234:1-6.
14. Tracey D, Klareskog L, Sasso EJ, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-279.
15. Kauffman MA, Gonzalez-Morón D, Garcea O, Villa AM. TNFSFR1A R92Q mutation, autoinflammatory symptoms and multiple sclerosis in a cohort from Argentina. Mol Biol Rep 2011;39:117-121.
16. Ermert M, Pantazis C, Duncker HR, Grimminger F, Seeger W, Ermert L. In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. Cytokine 2003;22:89-100.
17. Xanthoulea S, Pasparakis M, Kousteni S, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004;200:367-376.